Gaucher Disease Type 3
13 clinical trials · Condition
◉ Watch Gaucher Disease Type 3
| Record | Firm | Date |
|---|---|---|
| Phase 1/2 Study of CAN103 in Subjects With Gaucher Disease (NCT05447494) | CANbridge (Suzhou) Bio-pharma Co., Ltd. | 2022-07-11 |
| PEARL (PrEnAtal Enzyme Replacement Therapy for Lysosomal Storage Disorders) (NCT04532047) | University of California, San Francisco | 2021-07-01 |
| A Multicenter, Safety and Efficacy Study of Taliglucerase Alfa in Subjects With Type 3 Gaucher Disease (NCT04002830) | Ari Zimran | 2020-11-20 |
| Venglustat in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3 With Venglustat Monotherapy Extension (NCT02843035) | Genzyme, a Sanofi Company | 2017-01-04 |
| The Effect of Velaglucerase Alfa (Vpriv) on Skeletal Development in Pediatric Gaucher Disease (NCT02528617) | Baylor Research Institute | 2015-07-01 |
| Efficacy and Safety Study of Velaglucerase Alfa in Children and Adolescents With Type 3 Gaucher Disease (NCT01685216) | Shire | 2012-09-14 |
Track Gaucher Disease Type 3 automatically
Every clearance here is in the API, with alerts when new ones post.